MorphoSys Granted Further U.S. Patent for its Core Antibody Technology HuCAL

27 Sep 2007 - MorphoSys AG announced that the U.S. Patent & Trademark Office has granted a fifth U.S. patent stemming from MorphoSys's base HuCAL (Human Combinatorial Antibody Library) patent family, providing extended protection to MorphoSys's core technology. The new patent captures HuCAL's modular design at the DNA level, providing solid product claim protection in the U.S.
 
A first HuCAL patent, which is now complemented by the new patent, was issued by the U.S. Patent Office in 2001. HuCAL patents have been granted in the United States, in Australia and at the European Patent Office. To date, MorphoSys has had more than fifteen granted patents and has more than 40 applications pending worldwide.

www.bionity.com/news/e/70706

News
Further news on this topic:
www.bionity.com/news/e/more/70706
Contact
Request information on this article:
www.bionity.com/news/e/info/70706


© Chemie.DE Information Service GmbH
http://www.bionity.com/news/e/70706
Seydelstr. 28 · 10117 Berlin
info@chemie.de · Tel: +49 (0)30 20 45 68 - 0